BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences - KFVS12 News & Weather Cape Girardeau, Carbondale, Poplar Bluff

BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences

  • SPONSORED BY SOUTHEAST HEALTHMore>>

  • BJC changes charity care standards

    BJC changes charity care standards

    Sunday, April 20 2014 1:01 PM EDT2014-04-20 17:01:10 GMT
    Charity care has long been a core mission of BJC HealthCare, but the St. Louis area's largest employer is cutting back amid increasing financial pressures.
    Charity care has long been a core mission of BJC HealthCare, but the St. Louis area's largest employer is cutting back amid increasing financial pressures.
  • Clock ticking for states to adopt health exchanges

    Clock ticking for states to adopt health exchanges

    Friday, April 18 2014 2:39 PM EDT2014-04-18 18:39:20 GMT
    More than 30 states that defaulted to the federal government to run their health insurance markets under President Barack Obama's health care law must decide if they want to take a crack at it themselves. Time...
    More than 30 states that defaulted to the federal government to run their health insurance markets under President Barack Obama's health care law must decide if they want to take a crack at it themselves. Time is...
  • Blood test aims to predict breast cancer's return

    Blood test aims to predict breast cancer's return

    A new blood test may one day help predict the recurrence of breast cancer and also a woman's response to breast cancer treatment, researchers report.
    A new blood test may one day help predict the recurrence of breast cancer and also a woman's response to breast cancer treatment, researchers report.

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE BioSpecifics Technologies Corp.

LYNBROOK, N.Y., Feb. 19, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, today announced that BioSpecifics' President, Tom Wegman, will present at the following upcoming investor conferences.

  • RBC Capital Markets' 2014 Global Healthcare Conference (New York, NY)
    Wednesday, February 26, 2014 at 4:05 p.m. EST
  • Cowen and Company 34th Annual Health Care Conference (Boston, MA)
    Monday, March 3, 2014 at 4:50 p.m. EST
  • ROTH Capital Partners 26th Annual Conference (Laguna Niguel, CA)
    Tuesday, March 11, 2014 at 4:00 p.m. PDT

The live webcasts of these presentations can be accessed under "Events and Presentation" in the Investors section of the Company's website at www.biospecifics.com.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is approved for marketing as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm and for Peyronie's disease in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. (Auxilium). Auxilium is partnered with Actelion Pharmaceuticals Ltd. for the marketing of XIAFLEX in Canada and Australia, and Swedish Orphan Biovitrium AB for the marketing of XIAPEX® (the EU tradename for CCH) in 71 Eurasian and African countries for the treatment of Dupuytren's contracture, and Peyronie's disease pending applicable regulatory approvals. CCH is in clinical development for the treatment of several additional promising indications. Auxilium is testing CCH for frozen shoulder syndrome in a Phase 2b study and also for cellulite in a Phase 2a study. BioSpecifics is currently managing the development of CCH for the treatment of human and canine lipomas. For more information, please visit www.biospecifics.com.

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

310 Broadway
Cape Girardeau, MO 63701

FCC Public File
publicfile@kfvs12.com
573-335-1212
EEO Report
Closed Captioning

All content © Copyright 2000 - 2014 Worldnow and KFVS12. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.